REGN - Regeneron Pharmaceuticals, Inc.
| Previous Close | 298.37 |
| Open | 297.26 |
| Bid | 300.96 x 1100 |
| Ask | 301.08 x 1200 |
| Day's Range | 297.08 - 303.30 |
| 52 Week Range | 287.66 - 442.00 |
| Volume | 360,502 |
| Avg. Volume | 913,403 |
| Market Cap | 32.977B |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | 14.25 |
| EPS (TTM) | 21.11 |
| Earnings Date | Aug 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 391.16 |
- Zacks•4 hours ago
Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs
Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.
- GuruFocus.com•3 days ago
Stocks That Fell to 3-Year Lows in the Week of July 12
Regeneron Pharmaceuticals Inc., Ryanair Holdings PLC, Iron Mountain Inc. and Molson Coors Brewing Co. have declined to their respective three-year lows Continue reading...
- Zacks•6 days ago
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
- Zacks•6 days ago
FDA Accepts Sanofi's BLA for Myeloma Candidate to Review
The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.
- GuruFocus.com•7 days ago
David Herro and Bill Nygren Comment on Regeneron Pharmaceuticals
Guru stock highlight
- GuruFocus.com•7 days ago
David Herro and Bill Nygren's 2nd Quarter Oakmark Global Select Fund Commentary
Discussion of markets and holdings
- Simply Wall St.•8 days ago
Why Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Looks Like A Quality Company
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- PR Newswire•9 days ago
Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019
TARRYTOWN, N.Y. , July 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2019 financial and operating results on Tuesday, August ...
- Zacks•13 days ago
Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
- Zacks•15 days ago
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
- Zacks•15 days ago
Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.
- Zacks•16 days ago
Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
- PR Newswire•16 days ago
Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted conditional marketing authorization for Libtayo® (cemiplimab) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. "With no other medical treatments approved for advanced CSCC in the EU, Libtayo represents an important new option for patients affected with this advanced skin cancer who cannot be cured by surgery or radiation," said Axel Hauschild, M.D., Ph.D., an investigator in the pivotal CSCC clinical program and Professor and Head of the Interdisciplinary Skin Cancer Center at the University Hospital Schleswig-Holstein in Kiel, Germany.
- Motley Fool•17 days ago
3 Top Biotech Stocks to Add to Your Watchlist
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
- Zacks•20 days ago
Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
- Reuters•21 days ago
UPDATE 2-FDA approves expanded label for Regeneron/Sanofi's Dupixent
The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine. The expanded label, which could significantly boost annual sales, is for use with other medicines to treat patients suffering from chronic rhinosinusitis with nasal polyps, the companies said in a joint statement. The FDA first approved Dupixent in 2017 for moderate-to-severe atopic dermatitis, or eczema, and in 2018 it won U.S. approval to treat moderate-to-severe asthma as well.
- PR Newswire•21 days ago
FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery which often cannot control this disease.
- PR Newswire•21 days ago
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery, which often cannot control this disease.
- Zacks•21 days ago
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
- Benzinga•21 days ago
The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
- Motley Fool•22 days ago
The 10 Biggest Biotech Stocks
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
- Investopedia•22 days ago
Regeneron Pharma Turnaround Gains Steam
Regeneron Pharma shares have been on the rise after positive clinical data and a new strategy designed to increase patient access.
- Zacks•23 days ago
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
- MarketWatch•25 days ago
This would be the worst-case scenario for health stocks, according to UBS
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
